ClinicalTrials.gg
CompletedNCT00444457Updated Oct 15, 2012Results posted

Study Evaluating 13-valent Pneumococcal Conjugate Vaccine In Healthy Infants

A Phase 3 interventional study of 13-valent Pneumococcal Conjugate Vaccine and 7vPnC in Vaccines, Pneumococcal, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 78 sites in United States. Open to participants aged 42 Days to 98 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-10-15.

Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,712
Allocation
Randomized
Ages
42 Days to 98 Days
Sex
All
01

Study summary

The purpose of this study will be to evaluate safety, tolerability and immunogenicity of three lots of 13-valent pneumococcal vaccine given to healthy infants. Lots will be studied for consistency of the immune response, as well as for non-inferiority and safety as compared to 7-valent Pneumococcal Conjugate Vaccine.

02

Conditions studied

  • Vaccines, Pneumococcal

Keywords

  • Vaccine
  • Infants
  • Pneumococcal Conjugate Vaccines
  • Vaccines, Pneumococcal
03

In context

Lead sponsor

Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 484 studies on the registry; none are open to participants now.

First submitted before Wyeth became part of Pfizer.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
42 Days to 98 Days
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy 2 month old infants
  • Available for the duration of the study and reachable by telephone
  • Able to complete two blood drawing procedures during the study

Exclusion criteria

Exclusion criteria:

  • Previous vaccination, or history of allergic reaction to vaccines or vaccine components
  • Bleeding disorder, immune deficiency or significant chronic or congenital disease
  • Previous receipt of blood products or immune globulin
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,712 participants (actual)

Study arms

  • Experimental
    1

    Biological: 13-valent Pneumococcal Conjugate Vaccine

  • Experimental
    2

    Biological: 13-valent Pneumococcal Conjugate Vaccine

  • Experimental
    3

    Biological: 13-valent Pneumococcal Conjugate Vaccine

  • Active comparator
    4

    Biological: 7vPnC

Interventions

  • 0.5 mL of study vaccine administered IM at 2, 4, 6, and 12 months of age.

  • Biological7vPnC

    0.5 mL of study vaccine administered IM at 2, 4, 6, and 12 months of age.

06

What researchers measure

Primary outcomes

  1. Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody in the Three 13vPnC Groups 1 Month After the Infant Series

    Antibody geometric mean concentration (GMC) as measured by micrograms per milliliter (mcg/mL) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% confidence intervals (CI) were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw.

    Time frame: 1 Month after the infant series (7 Months of age)

  2. Percentage of Participants Achieving Predefined Antibody Level ≥0.1 International Units Per Milliliter (IU/mL) for Tetanus Toxoid in the Combined 13vPnC Group Relative to 7vPnC Group 1 Month After the Infant Series

    Percentage of participants achieving predefined antibody threshold ≥0.1 IU/ mL along with the corresponding 95% CI for concomitant antigen tetanus toxoid are presented. Exact 2-sided CI was based on the observed proportion of participants. Combined 13vPnC group includes participants randomized to pilot lot 1, pilot lot 2, or the manufacturing lot.

    Time frame: 1 month after the infant series (7 months of age)

  3. Percentage of Participants Achieving Predefined Antibody Level ≥1:8 for Poliovirus in the Combined 13vPnC Group Relative to 7vPnC Group 1 Month After the Infant Series

    Percentage of participants achieving predefined antibody threshold ≥1:8 along with the corresponding 95% CI for concomitant antigen poliovirus type 1, type 2, and type 3 (Sabin strains 1, 2, 3) are presented. Exact 2-sided CI was based on the observed proportion of participants. Combined 13vPnC group includes participants randomized to pilot lot 1, pilot lot 2, or the manufacturing lot.

    Time frame: 1 month after the infant series (7 months of age)

  4. Percentage of Participants Achieving Predefined Antibody Level ≥10.0 Milli-International Units Per Milliliter (mIU/mL) for Hepatitis B in the Combined 13vPnC Group Relative to 7vPnC Group 1 Month After the Infant Series

    Percentage of participants achieving predefined antibody threshold ≥10.0 mIU/ mL along with the corresponding 95% CI for concomitant antigen hepatitis B are presented. Exact 2-sided CI was based on the observed proportion of participants. Combined 13vPnC group includes participants randomized to pilot lot 1, pilot lot 2, or the manufacturing lot.

    Time frame: 1 month after the infant series (7 months of age)

Secondary outcomes

  1. Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥0.35 Mcg/mL in the Three 13vPnC Groups 1 Month After the Infant Series

    Percentage of participants achieving predefined antibody threshold ≥0.35mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.

    Time frame: 1 month after the infant series (7 months of age)

  2. Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥0.35 Mcg/mL in the Three 13vPnC Groups 1 Month After the Toddler Dose

    Percentage of participants achieving predefined antibody threshold ≥0.35 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.

    Time frame: 1 month after the toddler dose (13 months of age)

  3. Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥1.00 Mcg/mL in the Combined 13vPnC Group 1 Month After the Infant Series

    Percentage of participants achieving predefined antibody threshold ≥1.00 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.

    Time frame: 1 month after the infant series (7 months of age)

  4. Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥1.00 Mcg/mL in the Three 13vPnC Groups 1 Month After the Toddler Dose

    Percentage of participants achieving predefined antibody threshold ≥1.00 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.

    Time frame: 1 month after the toddler dose (13 months of age)

  5. Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody in the Three 13vPnC Groups 1 Month After the Toddler Dose

    Antibody geometric mean concentration (GMC) as measured by mcg/mL for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% confidence intervals (CI) were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw.

    Time frame: 1 month after the toddler dose (13 months of age)

Other outcomes

  1. Percentage of Participants Reporting Local Reactions in the Three 13vPnC Groups and 7vPnC Group: Infant Series Dose 1 (2 Months of Age)

    Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.

    Time frame: Within 7 days after dose (2 months of age)

  2. Percentage of Participants Reporting Local Reactions in the Three 13vPnC Groups and 7vPnC Group: Infant Series Dose 2 (4 Months of Age)

    Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 cm to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.

    Time frame: Within 7 days after dose (4 months of age)

  3. Percentage of Participants Reporting Local Reactions in the Three 13vPnC Groups and 7vPnC Group: Infant Series Dose 3 (6 Months of Age)

    Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 cm to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.

    Time frame: Within 7 days after dose (6 months of age)

  4. Percentage of Participants Reporting Local Reactions in the Combined 13vPnC Group and 7vPnC Group: Toddler Dose (12 Months of Age)

    Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 cm to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.

    Time frame: Within 7 days after dose (12 months of age)

  5. Percentage of Participants Reporting Systemic Events in the Three 13vPnC Groups and 7vPnC Group: Infant Series Dose 1 (2 Months of Age)

    Systemic events (any fever ≥ 38 degrees Celsius \[C\], decreased appetite, irritability, increased sleep, decreased sleep, and hives \[urticaria\]) were reported using an electronic diary. Participants may be represented in more than 1 category.

    Time frame: Within 7 days after dose (2 months of age)

  6. Percentage of Participants Reporting Systemic Events in the Three 13vPnC Groups and 7vPnC Group: Infant Series Dose 2 (4 Months of Age)

    Systemic events (any fever ≥ 38 degrees C, decreased appetite, irritability, increased sleep, decreased sleep, and hives \[urticaria\]) were reported using an electronic diary. Participants may be represented in more than 1 category.

    Time frame: Within 7 days after dose (4 months of age)

  7. Percentage of Participants Reporting Systemic Events in the Three 13vPnC Groups and 7vPnC Group: Infant Series Dose 3 (6 Months of Age)

    Systemic events (any fever ≥ 38 degrees C, decreased appetite, irritability, increased sleep, decreased sleep, and hives \[urticaria\]) were reported using an electronic diary. Participants may be represented in more than 1 category.

    Time frame: Within 7 days after dose (6 months of age)

  8. Percentage of Participants Reporting Systemic Events in the Combined 13vPnC Group and 7vPnC Group: Toddler Dose (12 Months of Age)

    Systemic events (any fever ≥ 38 degrees C, decreased appetite, irritability, increased sleep, decreased sleep, and hives \[urticaria\]) were reported using an electronic diary. Participants may be represented in more than 1 category.

    Time frame: Within 7 days after dose (12 months of age)

07

Results

Posted Jul 14, 2010
Limitations and caveats
Commercially available Measles, Mumps, and Rubella-varicella vaccine (MMR-varicella) was not available as planned; the alternate of a commercially available MMR and a commercially available varicella vaccine was administered in separate injections.

Participant flow

Infant Series
Participant flow — Infant Series
Milestone13vPnC (Pilot Lot 1)13vPnC (Pilot Lot 2)13vPnC (Manufacturing Lot)7vPnC
Started489488489246
Vaccinated dose 1486484485244
Vaccinated dose 2455447455228
Vaccinated dose 3442435438225
Completed435427428218
Not completed54616128
Withdrew: Other0100
Withdrew: Parent or legal guardian request18293414
Withdrew: Lost to follow-up101176
Withdrew: Protocol violation16863
Withdrew: Failed to return5442
Withdrew: Investigator request4332
Withdrew: Other0240
Withdrew: Adverse event1220
Withdrew: Death0111
After Infant Series
Participant flow — After Infant Series
Milestone13vPnC (Pilot Lot 1)13vPnC (Pilot Lot 2)13vPnC (Manufacturing Lot)7vPnC
Started435427427218
Completed415397408208
Not completed20301910
Withdrew: Other0111
Withdrew: Parent or legal guardian request41163
Withdrew: Failed to return7651
Withdrew: Lost to follow-up5552
Withdrew: Protocol violation2422
Withdrew: Adverse event2200
Withdrew: Investigator request0001
Withdrew: Other0100
Toddler Dose
Participant flow — Toddler Dose
Milestone13vPnC (Pilot Lot 1)13vPnC (Pilot Lot 2)13vPnC (Manufacturing Lot)7vPnC
Started415397408208
Completed408391404200
Not completed7648
Withdrew: Lost to follow-up4113
Withdrew: Failed to return2213
Withdrew: Parent or legal guardian request0321
Withdrew: Protocol violation1001

Outcome measures

PrimaryGeometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody in the Three 13vPnC Groups 1 Month After the Infant Series

Antibody geometric mean concentration (GMC) as measured by micrograms per milliliter (mcg/mL) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% confidence intervals (CI) were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw.

Time frame:
1 Month after the infant series (7 Months of age)
Reported as:
Geometric mean · GMC mcg/mL
Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody in the Three 13vPnC Groups 1 Month After the Infant Series
GMC mcg/mL13vPnC (Pilot Lot 1)13vPnC (Pilot Lot 2)13vPnC (Manufacturing Lot)
Common serotypes - serotype 4 (n=411, 404, 398)1.33 (1.24 to 1.43)1.34 (1.25 to 1.44)1.75 (1.63 to 1.88)
Common serotypes - serotype 6B (n=409, 401, 396)2.89 (2.58 to 3.23)2.15 (1.91 to 2.42)2.54 (2.27 to 2.85)
Common serotypes - serotype 9V (n=411, 403, 396)1.05 (0.98 to 1.12)1.11 (1.04 to 1.19)1.11 (1.04 to 1.19)
Common serotypes - serotype 14 (n=398. 387, 387)4.97 (4.59 to 5.37)5.13 (4.70 to 5.59)5.18 (4.72 to 5.69)
Common serotypes - serotype 18C (n=413, 401, 398)1.30 (1.22 to 1.38)1.34 (1.24 to 1.44)1.48 (1.38 to 1.58)
Common serotypes - serotype 19F (n=408, 399, 398)1.85 (1.71 to 1.99)2.07 (1.92 to 2.24)2.59 (2.40 to 2.78)
Common serotypes - serotype 23F (n=411, 402, 399)1.24 (1.13 to 1.36)1.27 (1.15 to 1.40)1.03 (0.94 to 1.14)
Additional serotypes - serotype 1 (n=411, 403,395)1.62 (1.50 to 1.76)1.81 (1.66 to 1.98)1.91 (1.76 to 2.07)
Additional serotypes - serotype 3 (n=406, 391,393)0.52 (0.48 to 0.55)0.56 (0.52 to 0.61)0.61 (0.57 to 0.66)
Additional serotypes - serotype 5 (n=412, 402,393)1.35 (1.24 to 1.47)1.05 (0.96 to 1.14)1.35 (1.25 to 1.47)
Additional serotypes - serotype 6A (n=413,402,398)2.40 (2.21 to 2.61)2.10 (1.92 to 2.29)2.12 (1.96 to 2.30)
Additional serotypes - serotype 7F (n=412,401,397)2.54 (2.37 to 2.71)2.52 (2.35 to 2.70)2.67 (2.50 to 2.85)
Additional serotype - serotype 19A (n=411,403,397)1.85 (1.71 to 2.00)2.00 (1.85 to 2.16)1.88 (1.74 to 2.02)
Statistical analysis
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Pilot Lot 2) · Difference in log-transformed gm: -0.01 · 95% CI -0.11 to 0.092-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Manufacturing Lot) · Difference in log-transformed gm: -0.27 · 95% CI -0.38 to -0.172-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 2) vs 13vPnC (Manufacturing Lot) · Difference in log-transformed gm: -0.27 · 95% CI -0.37 to -0.162-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Pilot Lot 2) · Difference in log-transformed gm: 0.30 · 95% CI 0.13 to 0.462-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Manufacturing Lot) · Difference in log-transformed gm: 0.13 · 95% CI -0.04 to 0.292-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 2) vs 13vPnC (Manufacturing Lot) · Difference in log-transformed gm: -0.17 · 95% CI -0.33 to -0.012-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Pilot Lot 2) · Difference in log-transformed gm: -0.06 · 95% CI -0.16 to 0.042-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Manufacturing Lot) · Difference in log-transformed gm: -0.06 · 95% CI -0.16 to 0.042-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 2) vs 13vPnC (Manufacturing Lot) · Difference in log-transformed gm: 0.00 · 95% CI -0.10 to 0.102-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Pilot Lot 2) · Difference in log-transformed gm: -0.03 · 95% CI -0.15 to 0.092-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Manufacturing Lot) · Difference in log-transformed gm: -0.04 · 95% CI -0.16 to 0.082-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 2) vs 13vPnC (Manufacturing Lot) · Difference in log-transformed gm: -0.01 · 95% CI -0.13 to 0.112-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Pilot Lot 2) · Difference in log-transformed gm: -0.03 · 95% CI -0.13 to 0.072-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Manufacturing Lot) · Difference in log-transformed gm: -0.13 · 95% CI -0.23 to -0.032-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 2) vs 13vPnC (Manufacturing Lot) · Difference in log-transformed gm: -0.10 · 95% CI -0.20 to -0.002-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Pilot Lot 2) · Difference in log-transformed gm: -0.11 · 95% CI -0.22 to -0.012-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Manufacturing Lot) · Difference in log-transformed gm: -0.34 · 95% CI -0.44 to -0.232-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 2) vs 13vPnC (Manufacturing Lot) · Difference in log-transformed gm: -0.22 · 95% CI -0.33 to -0.112-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Pilot Lot 2) · Difference in log-transformed gm: -0.03 · 95% CI -0.16 to 0.112-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Manufacturing Lot) · Difference in log-transformed gm: 0.18 · 95% CI 0.04 to 0.312-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 2) vs 13vPnC (Manufacturing Lot) · Difference in log-transformed gm: 0.20 · 95% CI 0.07 to 0.342-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Pilot Lot 2) · Difference in log-transformed gm: -0.11 · 95% CI -0.23 to 0.012-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Manufacturing Lot) · Difference in log-transformed gm: -0.16 · 95% CI -0.28 to -0.042-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 2) vs 13vPnC (Manufacturing Lot) · Difference in log-transformed gm: -0.05 · 95% CI -0.17 to 0.062-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Pilot Lot 2) · Difference in log-transformed gm: -0.09 · 95% CI -0.19 to 0.022-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Manufacturing Lot) · Difference in log-transformed gm: -0.18 · 95% CI -0.28 to -0.072-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 2) vs 13vPnC (Manufacturing Lot) · Difference in log-transformed gm: -0.09 · 95% CI -0.19 to 0.022-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Pilot Lot 2) · Difference in log-transformed gm: 0.25 · 95% CI 0.13 to 0.372-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Manufacturing Lot) · Difference in log-transformed gm: 0.00 · 95% CI -0.12 to 0.122-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 2) vs 13vPnC (Manufacturing Lot) · Difference in log-transformed gm: -0.25 · 95% CI -0.37 to -0.132-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Pilot Lot 2) · Difference in log-transformed gm: 0.14 · 95% CI 0.02 to 0.252-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Manufacturing Lot) · Difference in log-transformed gm: 0.12 · 95% CI 0.01 to 0.242-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 2) vs 13vPnC (Manufacturing Lot) · Difference in log-transformed gm: -0.01 · 95% CI -0.13 to 0.112-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Pilot Lot 2) · Difference in log-transformed gm: 0.01 · 95% CI -0.09 to 0.102-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Manufacturing Lot) · Difference in log-transformed gm: -0.05 · 95% CI -0.14 to 0.042-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 2) vs 13vPnC (Manufacturing Lot) · Difference in log-transformed gm: -0.06 · 95% CI -0.15 to 0.042-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Pilot Lot 2) · Difference in log-transformed gm: -0.08 · 95% CI -0.19 to 0.032-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Manufacturing Lot) · Difference in log-transformed gm: -0.02 · 95% CI -0.12 to 0.092-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 2) vs 13vPnC (Manufacturing Lot) · Difference in log-transformed gm: 0.06 · 95% CI -0.05 to 0.172-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
PrimaryPercentage of Participants Achieving Predefined Antibody Level ≥0.1 International Units Per Milliliter (IU/mL) for Tetanus Toxoid in the Combined 13vPnC Group Relative to 7vPnC Group 1 Month After the Infant Series

Percentage of participants achieving predefined antibody threshold ≥0.1 IU/ mL along with the corresponding 95% CI for concomitant antigen tetanus toxoid are presented. Exact 2-sided CI was based on the observed proportion of participants. Combined 13vPnC group includes participants randomized to pilot lot 1, pilot lot 2, or the manufacturing lot.

Time frame:
1 month after the infant series (7 months of age)
Reported as:
Number · observed percentage of participants
Percentage of Participants Achieving Predefined Antibody Level ≥0.1 International Units Per Milliliter (IU/mL) for Tetanus Toxoid in the Combined 13vPnC Group Relative to 7vPnC Group 1 Month After the Infant Series
observed percentage of participantsCombined 13vPnC7vPnC
Percentage of Participants Achieving Predefined Antibody Level ≥0.1 International Units Per Milliliter (IU/mL) for Tetanus Toxoid in the Combined 13vPnC Group Relative to 7vPnC Group 1 Month After the Infant Series98.4 (95.3 to 99.7)98.5 (95.6 to 99.7)
Statistical analysis
  • Combined 13vPnC vs 7vPnC · Difference: -0.1 · 95% CI -3.3 to 3.0Exact 2-sided CI for difference in proportions (combined 13vPnC, 7vPnC) expressed as a percentage.
PrimaryPercentage of Participants Achieving Predefined Antibody Level ≥1:8 for Poliovirus in the Combined 13vPnC Group Relative to 7vPnC Group 1 Month After the Infant Series

Percentage of participants achieving predefined antibody threshold ≥1:8 along with the corresponding 95% CI for concomitant antigen poliovirus type 1, type 2, and type 3 (Sabin strains 1, 2, 3) are presented. Exact 2-sided CI was based on the observed proportion of participants. Combined 13vPnC group includes participants randomized to pilot lot 1, pilot lot 2, or the manufacturing lot.

Time frame:
1 month after the infant series (7 months of age)
Reported as:
Number · observed percentage of participants
Percentage of Participants Achieving Predefined Antibody Level ≥1:8 for Poliovirus in the Combined 13vPnC Group Relative to 7vPnC Group 1 Month After the Infant Series
observed percentage of participantsCombined 13vPnC7vPnC
Poliovirus type 1 (n=183, 187)100.0 (98.0 to 100.0)100.0 (98.0 to 100.0)
Poliovirus type 2 (n=181, 186)98.9 (96.1 to 99.9)99.5 (97.1 to 100.0)
Poliovirus type 3 (n=182, 186)100.0 (98.0 to 100.0)99.5 (97.1 to 100.0)
Statistical analysis
  • Combined 13vPnC vs 7vPnC · Difference: 0.0 · 95% CI -2.1 to 2.0Exact 2-sided CI for difference in proportions (combined 13vPnC, 7vPnC) expressed as a percentage.
  • Combined 13vPnC vs 7vPnC · Difference: -0.6 · 95% CI -3.4 to 2.0Exact 2-sided CI for difference in proportions (combined 13vPnC, 7vPnC) expressed as a percentage.
  • Combined 13vPnC vs 7vPnC · Difference: 0.5 · 95% CI -1.5 to 3.0Exact 2-sided CI for difference in proportions (combined 13vPnC, 7vPnC) expressed as a percentage.
PrimaryPercentage of Participants Achieving Predefined Antibody Level ≥10.0 Milli-International Units Per Milliliter (mIU/mL) for Hepatitis B in the Combined 13vPnC Group Relative to 7vPnC Group 1 Month After the Infant Series

Percentage of participants achieving predefined antibody threshold ≥10.0 mIU/ mL along with the corresponding 95% CI for concomitant antigen hepatitis B are presented. Exact 2-sided CI was based on the observed proportion of participants. Combined 13vPnC group includes participants randomized to pilot lot 1, pilot lot 2, or the manufacturing lot.

Time frame:
1 month after the infant series (7 months of age)
Reported as:
Number · observed percentage of participants
Percentage of Participants Achieving Predefined Antibody Level ≥10.0 Milli-International Units Per Milliliter (mIU/mL) for Hepatitis B in the Combined 13vPnC Group Relative to 7vPnC Group 1 Month After the Infant Series
observed percentage of participantsCombined 13vPnC7vPnC
Percentage of Participants Achieving Predefined Antibody Level ≥10.0 Milli-International Units Per Milliliter (mIU/mL) for Hepatitis B in the Combined 13vPnC Group Relative to 7vPnC Group 1 Month After the Infant Series100.0 (97.6 to 100.0)100.0 (97.9 to 100.0)
Statistical analysis
  • Combined 13vPnC vs 7vPnC · Difference: 0.0 · 95% CI -2.4 to 2.2Exact 2-sided CI for difference in proportions (combined 13vPnC, 7vPnC) expressed as a percentage.
SecondaryPercentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥0.35 Mcg/mL in the Three 13vPnC Groups 1 Month After the Infant Series

Percentage of participants achieving predefined antibody threshold ≥0.35mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.

Time frame:
1 month after the infant series (7 months of age)
Reported as:
Number · observed percentage of participants
Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥0.35 Mcg/mL in the Three 13vPnC Groups 1 Month After the Infant Series
observed percentage of participants13vPnC (Pilot Lot 1)13vPnC (Pilot Lot 2)13vPnC (Manufacturing Lot)
Common serotypes - serotype 4 (n=411, 404, 398)97.6 (95.6 to 98.8)95.5 (93.0 to 97.3)98.5 (96.7 to 99.4)
Common serotypes - serotype 6B (n=409, 401, 396)94.9 (92.3 to 96.8)89.5 (86.1 to 92.3)94.4 (91.7 to 96.5)
Common serotypes - serotype 9V (n=411, 403, 396)95.4 (92.9 to 97.2)95.5 (93.0 to 97.3)96.5 (94.1 to 98.1)
Common serotypes - serotype 14 (n=398, 387, 387)99.2 (97.8 to 99.8)99.0 (97.4 to 99.7)98.2 (96.3 to 99.3)
Common serotypes - serotype 18C (n=413, 401, 398)97.8 (95.9 to 99.0)95.8 (93.3 to 97.5)98.0 (96.1 to 99.1)
Common serotypes - serotype 19F (n=408, 399, 398)97.8 (95.9 to 99.0)97.5 (95.4 to 98.8)99.2 (97.8 to 99.8)
Common serotypes - serotype 23F (n=411, 402, 399)91.2 (88.1 to 93.8)88.1 (84.5 to 91.1)87.2 (83.5 to 90.3)
Additional serotypes - serotype 1 (n=411, 403,395)97.8 (95.9 to 99.0)97.0 (94.9 to 98.5)98.5 (96.7 to 99.4)
Additional serotypes - serotype 3 (n=406, 391,393)68.5 (63.7 to 73.0)72.4 (67.7 to 76.8)79.1 (74.8 to 83.0)
Additional serotypes - serotype 5 (n=412, 402,393)94.2 (91.5 to 96.2)90.3 (87.0 to 93.0)94.4 (91.6 to 96.5)
Additional serotypes - serotype 6A (n=413,402,398)98.1 (96.2 to 99.2)95.5 (93.0 to 97.3)98.2 (96.4 to 99.3)
Additional serotypes - serotype 7F (n=412,401,397)99.8 (98.7 to 100.0)99.0 (97.5 to 99.7)99.7 (98.6 to 100.0)
Additional serotype - serotype 19A (n=411,403,397)98.1 (96.2 to 99.2)99.0 (97.5 to 99.7)98.7 (97.1 to 99.6)
Statistical analysis
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Pilot Lot 2) · Difference: 2.0 · 95% CI -0.51 to 4.75
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Manufacturing Lot) · Difference: -0.9 · 95% CI -3.09 to 1.10
  • 13vPnC (Pilot Lot 2) vs 13vPnC (Manufacturing Lot) · Difference: -2.9 · 95% CI -5.58 to -0.58
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Pilot Lot 2) · Difference: 5.3 · 95% CI 1.55 to 9.19
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Manufacturing Lot) · Difference: 0.4 · 95% CI -2.77 to 3.66
  • 13vPnC (Pilot Lot 2) vs 13vPnC (Manufacturing Lot) · Difference: -4.9 · 95% CI -8.82 to -1.10
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Pilot Lot 2) · Difference: -0.2 · 95% CI -3.13 to 2.83
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Manufacturing Lot) · Difference: -1.1 · 95% CI -3.97 to 1.73
  • 13vPnC (Pilot Lot 2) vs 13vPnC (Manufacturing Lot) · Difference: -0.9 · 95% CI -3.81 to 1.88
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Pilot Lot 2) · Difference: 0.3 · 95% CI -1.27 to 1.95
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Manufacturing Lot) · Difference: 1.1 · 95% CI -0.60 to 3.01
  • 13vPnC (Pilot Lot 2) vs 13vPnC (Manufacturing Lot) · Difference: 0.8 · 95% CI -1.04 to 2.76
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Pilot Lot 2) · Difference: 2.1 · 95% CI -0.38 to 4.74
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Manufacturing Lot) · Difference: -0.2 · 95% CI -2.33 to 1.99
  • 13vPnC (Pilot Lot 2) vs 13vPnC (Manufacturing Lot) · Difference: -2.2 · 95% CI -4.89 to 0.23
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Pilot Lot 2) · Difference: 0.3 · 95% CI -1.93 to 2.60
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Manufacturing Lot) · Difference: -1.5 · 95% CI -3.46 to 0.28
  • 13vPnC (Pilot Lot 2) vs 13vPnC (Manufacturing Lot) · Difference: -1.8 · 95% CI -3.87 to 0.02
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Pilot Lot 2) · Difference: 3.2 · 95% CI -1.03 to 7.46
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Manufacturing Lot) · Difference: 4.0 · 95% CI -0.27 to 8.39
  • 13vPnC (Pilot Lot 2) vs 13vPnC (Manufacturing Lot) · Difference: 0.8 · 95% CI -3.75 to 5.46
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Pilot Lot 2) · Difference: 0.8 · 95% CI -1.48 to 3.18
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Manufacturing Lot) · Difference: -0.7 · 95% CI -2.78 to 1.34
  • 13vPnC (Pilot Lot 2) vs 13vPnC (Manufacturing Lot) · Difference: -1.5 · 95% CI -3.77 to 0.67
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Pilot Lot 2) · Difference: -3.9 · 95% CI -10.27 to 2.45
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Manufacturing Lot) · Difference: -10.7 · 95% CI -16.80 to -4.57
  • 13vPnC (Pilot Lot 2) vs 13vPnC (Manufacturing Lot) · Difference: -6.8 · 95% CI -12.76 to -0.74
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Pilot Lot 2) · Difference: 3.9 · 95% CI 0.15 to 7.69
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Manufacturing Lot) · Difference: -0.2 · 95% CI -3.52 to 3.09
  • 13vPnC (Pilot Lot 2) vs 13vPnC (Manufacturing Lot) · Difference: -4.1 · 95% CI -7.92 to -0.36
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Pilot Lot 2) · Difference: 2.5 · 95% CI 0.12 to 5.23
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Manufacturing Lot) · Difference: -0.2 · 95% CI -2.22 to 1.86
  • 13vPnC (Pilot Lot 2) vs 13vPnC (Manufacturing Lot) · Difference: -2.7 · 95% CI -5.39 to -0.27
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Pilot Lot 2) · Difference: 0.8 · 95% CI -0.47 to 2.30
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Manufacturing Lot) · Difference: 0.0 · 95% CI -1.12 to 1.18
  • 13vPnC (Pilot Lot 2) vs 13vPnC (Manufacturing Lot) · Difference: -0.7 · 95% CI -2.30 to 0.52
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Pilot Lot 2) · Difference: -1.0 · 95% CI -2.91 to 0.80
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Manufacturing Lot) · Difference: -0.7 · 95% CI -2.69 to 1.19
  • 13vPnC (Pilot Lot 2) vs 13vPnC (Manufacturing Lot) · Difference: 0.3 · 95% CI -1.40 to 2.04
SecondaryPercentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥0.35 Mcg/mL in the Three 13vPnC Groups 1 Month After the Toddler Dose

Percentage of participants achieving predefined antibody threshold ≥0.35 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.

Time frame:
1 month after the toddler dose (13 months of age)
Reported as:
Number · observed percentage of participants
Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥0.35 Mcg/mL in the Three 13vPnC Groups 1 Month After the Toddler Dose
observed percentage of participants13vPnC (Pilot Lot 1)13vPnC (Pilot Lot 2)13vPnC (Manufacturing Lot)
Common serotypes - serotype 4 (n=364, 342, 355)99.2 (97.6 to 99.8)99.1 (97.5 to 99.8)100.0 (99.0 to 100.0)
Common serotypes - serotype 6B (n=368,341,357)100.0 (99.0 to 100.0)100.0 (98.9 to 100.0)100.0 (99.0 to 100.0)
Common serotypes - serotype 9V (n=368,342,357)99.7 (98.5 to 100.0)99.7 (98.4 to 100.0)99.2 (97.6 to 99.8)
Common serotypes - serotype 14 (n=366,344,358)100.0 (99.0 to 100.0)99.7 (98.4 to 100.0)100.0 (99.0 to 100.0)
Common serotypes - serotype 18C (n=362,341,354)98.9 (97.2 to 99.7)98.5 (96.6 to 99.5)99.4 (98.0 to 99.9)
Common serotypes - serotype 19F (n=362,342,353)98.3 (96.4 to 99.4)98.8 (97.0 to 99.7)99.4 (98.0 to 99.9)
Common serotypes - serotype 23F (n=362,340,353)99.4 (98.0 to 99.9)99.1 (97.4 to 99.8)98.3 (96.3 to 99.4)
Additional serotypes - serotype 1 (n=367,344,357)100.0 (99.0 to 100.0)99.1 (97.5 to 99.8)99.2 (97.6 to 99.8)
Additional serotypes - serotype 3 (n=366,343,356)83.6 (79.4 to 87.3)80.8 (76.2 to 84.8)88.5 (84.7 to 91.6)
Additional serotypes - serotype 5 (n=368,343,357)99.7 (98.5 to 100.0)99.4 (97.9 to 99.9)99.7 (98.4 to 100.0)
Additional serotypes - serotype 6A (n=366,342,355)100.0 (99.0 to 100.0)100.0 (98.9 to 100.0)99.7 (98.4 to 100.0)
Additional serotypes - serotype 7F (n=366,343,358)100.0 (99.0 to 100.0)99.4 (97.9 to 99.9)99.4 (98.0 to 99.9)
Additional serotype - serotype 19A (n=362,341,353)100.0 (99.0 to 100.0)100.0 (98.9 to 100.0)100.0 (99.0 to 100.0)
Statistical analysis
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Pilot Lot 2) · Difference: 0.1 · 95% CI -1.61 to 1.81Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Manufacturing Lot) · Difference: -0.8 · 95% CI -2.39 to 0.23Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 2) vs 13vPnC (Manufacturing Lot) · Difference: -0.9 · 95% CI -2.54 to 0.20Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Pilot Lot 2) · Difference: 0.0 · 95% CI -1.02 to 1.11Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Manufacturing Lot) · Difference: 0.0 · 95% CI -1.03 to 1.04Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 2) vs 13vPnC (Manufacturing Lot) · Difference: 0.0 · 95% CI -1.13 to 1.06Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Pilot Lot 2) · Difference: 0.0 · 95% CI -1.25 to 1.37Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Manufacturing Lot) · Difference: 0.6 · 95% CI -0.76 to 2.18Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 2) vs 13vPnC (Manufacturing Lot) · Difference: 0.5 · 95% CI -0.87 to 2.18Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Pilot Lot 2) · Difference: 0.3 · 95% CI -0.74 to 1.62Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Manufacturing Lot) · Difference: 0.0 · 95% CI -1.03 to 1.04Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 2) vs 13vPnC (Manufacturing Lot) · Difference: -0.3 · 95% CI -1.61 to 0.76Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Pilot Lot 2) · Difference: 0.4 · 95% CI -1.52 to 2.39Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Manufacturing Lot) · Difference: -0.5 · 95% CI -2.30 to 1.04Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 2) vs 13vPnC (Manufacturing Lot) · Difference: -0.9 · 95% CI -2.87 to 0.74Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Pilot Lot 2) · Difference: -0.5 · 95% CI -2.55 to 1.50Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Manufacturing Lot) · Difference: -1.1 · 95% CI -3.06 to 0.57Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 2) vs 13vPnC (Manufacturing Lot) · Difference: -0.6 · 95% CI -2.44 to 1.00Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Pilot Lot 2) · Difference: 0.3 · 95% CI -1.21 to 2.05Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Manufacturing Lot) · Difference: 1.1 · 95% CI -0.52 to 3.16Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 2) vs 13vPnC (Manufacturing Lot) · Difference: 0.8 · 95% CI -1.05 to 2.87Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Pilot Lot 2) · Difference: 0.9 · 95% CI -0.17 to 2.53Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Manufacturing Lot) · Difference: 0.8 · 95% CI -0.20 to 2.44Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 2) vs 13vPnC (Manufacturing Lot) · Difference: -0.0 · 95% CI -1.79 to 1.66Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Pilot Lot 2) · Difference: 2.8 · 95% CI -2.85 to 8.55Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Manufacturing Lot) · Difference: -4.9 · 95% CI -9.99 to 0.21Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 2) vs 13vPnC (Manufacturing Lot) · Difference: -7.7 · 95% CI -13.14 to -2.37Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Pilot Lot 2) · Difference: 0.3 · 95% CI -1.00 to 1.84Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Manufacturing Lot) · Difference: 0.0 · 95% CI -1.27 to 1.30Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 2) vs 13vPnC (Manufacturing Lot) · Difference: -0.3 · 95% CI -1.84 to 1.02Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Pilot Lot 2) · Difference: 0.0 · 95% CI -1.04 to 1.08Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Manufacturing Lot) · Difference: 0.3 · 95% CI -0.76 to 1.56Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 2) vs 13vPnC (Manufacturing Lot) · Difference: 0.3 · 95% CI -0.83 to 1.56Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Pilot Lot 2) · Difference: 0.6 · 95% CI -0.47 to 2.09Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Manufacturing Lot) · Difference: 0.6 · 95% CI -0.48 to 2.00Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 2) vs 13vPnC (Manufacturing Lot) · Difference: -0.0 · 95% CI -1.59 to 1.49Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Pilot Lot 2) · Difference: 0.0 · 95% CI -1.04 to 1.09Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Manufacturing Lot) · Difference: 0.0 · 95% CI -1.05 to 1.04Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 2) vs 13vPnC (Manufacturing Lot) · Difference: 0.0 · 95% CI -1.09 to 1.07Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
SecondaryPercentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥1.00 Mcg/mL in the Combined 13vPnC Group 1 Month After the Infant Series

Percentage of participants achieving predefined antibody threshold ≥1.00 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.

Time frame:
1 month after the infant series (7 months of age)
Reported as:
Number · observed percentage of participants
Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥1.00 Mcg/mL in the Combined 13vPnC Group 1 Month After the Infant Series
observed percentage of participantsCombined 13vPnC
Common serotypes - serotype 4 (n=1213)70.7 (68.1 to 73.3)
Common serotypes - serotype 6B (n=1206)78.9 (76.4 to 81.1)
Common serotypes - serotype 9V (n=1210)55.7 (52.9 to 58.5)
Common serotypes - serotype 14 (n=1172)95.2 (93.8 to 96.4)
Common serotypes - serotype 18C (n=1212)68.7 (66.0 to 71.3)
Common serotypes - serotype 19F (n=1205)85.4 (83.3 to 87.3)
Common serotypes - serotype 23F (n=1212)60.1 (57.2 to 62.8)
Additional serotypes - serotype 1 (n=1209)75.2 (72.7 to 77.6)
Additional serotypes - serotype 3 (n=1190)21.3 (19.0 to 23.8)
Additional serotypes - serotype 5 (n=1207)60.3 (57.5 to 63.1)
Additional serotypes - serotype 6A (n=1213)85.1 (82.9 to 87.0)
Additional serotypes - serotype 7F (n=1210)92.8 (91.2 to 94.2)
Additional serotypes - serotype 19A (n=1211)80.8 (78.4 to 82.9)
SecondaryPercentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥1.00 Mcg/mL in the Three 13vPnC Groups 1 Month After the Toddler Dose

Percentage of participants achieving predefined antibody threshold ≥1.00 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants.

Time frame:
1 month after the toddler dose (13 months of age)
Reported as:
Number · observed percentage of participants
Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥1.00 Mcg/mL in the Three 13vPnC Groups 1 Month After the Toddler Dose
observed percentage of participants13vPnC (Pilot Lot 1)13vPnC (Pilot Lot 2)13vPnC (Manufacturing Lot)
Common serotypes - serotype 4 (n=364,342,355)86.0 (82.0 to 89.4)87.4 (83.4 to 90.7)92.7 (89.5 to 95.2)
Common serotypes - serotype 6B (n=368,341,357)99.5 (98.1 to 99.9)99.1 (97.5 to 99.8)99.7 (98.4 to 100.0)
Common serotypes - serotype 9V (n=368,342,357)80.7 (76.3 to 84.6)84.5 (80.2 to 88.2)85.4 (81.3 to 88.9)
Common serotypes - serotype 14 (n=366,344,358)98.6 (96.8 to 99.6)98.8 (97.0 to 99.7)98.3 (96.4 to 99.4)
Common serotypes - serotype 18C (n=362,341,354)79.6 (75.0 to 83.6)85.0 (80.8 to 88.7)89.5 (85.9 to 92.5)
Common serotypes - serotype 19F (n=362,342,353)94.5 (91.6 to 96.6)95.3 (92.5 to 97.3)97.7 (95.6 to 99.0)
Common serotypes - serotype 23F (n=362,340,353)91.7 (88.4 to 94.3)91.2 (87.6 to 94.0)89.8 (86.2 to 92.8)
Additional serotypes - serotype 1 (n=367,344,357)91.8 (88.5 to 94.4)91.0 (87.5 to 93.8)94.4 (91.5 to 96.5)
Additional serotypes - serotype 3 (n=366,343,356)32.0 (27.2 to 37.0)30.3 (25.5 to 35.5)36.8 (31.8 to 42.0)
Additional serotypes - serotype 5 (n=368,343,357)94.0 (91.1 to 96.2)91.0 (87.4 to 93.8)93.6 (90.5 to 95.9)
Additional serotypes - serotype 6A (n=366,342,355)99.2 (97.6 to 99.8)98.2 (96.2 to 99.4)99.2 (97.6 to 99.8)
Additional serotypes - serotype 7F (n=366,343,358)98.1 (96.1 to 99.2)96.2 (93.6 to 98.0)98.6 (96.8 to 99.5)
Additional serotype - serotype 19A (n=362,341,353)100.0 (99.0 to 100.0)99.4 (97.9 to 99.9)99.7 (98.4 to 100.0)
Statistical analysis
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Pilot Lot 2) · Difference: -1.4 · 95% CI -6.52 to 3.63Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Manufacturing Lot) · Difference: -6.7 · 95% CI -11.30 to -2.15Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 2) vs 13vPnC (Manufacturing Lot) · Difference: -5.2 · 95% CI -9.85 to -0.79Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Pilot Lot 2) · Difference: 0.3 · 95% CI -1.19 to 2.07Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Manufacturing Lot) · Difference: -0.3 · 95% CI -1.69 to 1.06Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 2) vs 13vPnC (Manufacturing Lot) · Difference: -0.6 · 95% CI -2.27 to 0.75Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Pilot Lot 2) · Difference: -3.8 · 95% CI -9.46 to 1.82Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Manufacturing Lot) · Difference: -4.7 · 95% CI -10.24 to 0.76Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 2) vs 13vPnC (Manufacturing Lot) · Difference: -0.9 · 95% CI -6.30 to 4.41Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Pilot Lot 2) · Difference: -0.2 · 95% CI -2.14 to 1.73Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Manufacturing Lot) · Difference: 0.3 · 95% CI -1.69 to 2.39Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 2) vs 13vPnC (Manufacturing Lot) · Difference: 0.5 · 95% CI -1.46 to 2.59Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Pilot Lot 2) · Difference: -5.5 · 95% CI -11.17 to 0.20Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Manufacturing Lot) · Difference: -10.0 · 95% CI -15.31 to -4.70Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 2) vs 13vPnC (Manufacturing Lot) · Difference: -4.5 · 95% CI -9.55 to 0.46Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Pilot Lot 2) · Difference: -0.8 · 95% CI -4.23 to 2.52Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Manufacturing Lot) · Difference: -3.3 · 95% CI -6.35 to -0.40Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 2) vs 13vPnC (Manufacturing Lot) · Difference: -2.4 · 95% CI -5.44 to 0.33Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Pilot Lot 2) · Difference: 0.5 · 95% CI -3.67 to 4.80Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Manufacturing Lot) · Difference: 1.9 · 95% CI -2.38 to 6.28Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 2) vs 13vPnC (Manufacturing Lot) · Difference: 1.4 · 95% CI -3.06 to 5.82Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Pilot Lot 2) · Difference: 0.8 · 95% CI -3.34 to 5.08Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Manufacturing Lot) · Difference: -2.6 · 95% CI -6.39 to 1.18Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 2) vs 13vPnC (Manufacturing Lot) · Difference: -3.4 · 95% CI -7.45 to 0.46Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Pilot Lot 2) · Difference: 1.6 · 95% CI -5.20 to 8.55Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Manufacturing Lot) · Difference: -4.8 · 95% CI -11.79 to 2.16Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 2) vs 13vPnC (Manufacturing Lot) · Difference: -6.5 · 95% CI -13.51 to 0.54Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Pilot Lot 2) · Difference: 3.1 · 95% CI -0.84 to 7.13Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Manufacturing Lot) · Difference: 0.5 · 95% CI -3.14 to 4.11Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 2) vs 13vPnC (Manufacturing Lot) · Difference: -2.6 · 95% CI -6.72 to 1.40Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Pilot Lot 2) · Difference: 0.9 · 95% CI -0.87 to 3.02Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Manufacturing Lot) · Difference: 0.0 · 95% CI -1.62 to 1.71Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 2) vs 13vPnC (Manufacturing Lot) · Difference: -0.9 · 95% CI -3.00 to 0.92Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Pilot Lot 2) · Difference: 1.9 · 95% CI -0.62 to 4.67Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Manufacturing Lot) · Difference: -0.5 · 95% CI -2.67 to 1.55Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 2) vs 13vPnC (Manufacturing Lot) · Difference: -2.4 · 95% CI -5.11 to -0.01Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Pilot Lot 2) · Difference: 0.6 · 95% CI -0.45 to 2.10Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Manufacturing Lot) · Difference: 0.3 · 95% CI -0.75 to 1.58Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
  • 13vPnC (Pilot Lot 2) vs 13vPnC (Manufacturing Lot) · Difference: -0.3 · 95% CI -1.86 to 1.05Exact unconditional 2-sided 95% CI on the pairwise difference in proportions; expressed as a percentage.
SecondaryGeometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody in the Three 13vPnC Groups 1 Month After the Toddler Dose

Antibody geometric mean concentration (GMC) as measured by mcg/mL for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% confidence intervals (CI) were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw.

Time frame:
1 month after the toddler dose (13 months of age)
Reported as:
Geometric mean · GMC mcg/mL
Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody in the Three 13vPnC Groups 1 Month After the Toddler Dose
GMC mcg/mL13vPnC (Pilot Lot 1)13vPnC (Pilot Lot 2)13vPnC (Manufacturing Lot)
Common serotypes - serotype 4 (n=364,342,355)2.29 (2.11 to 2.48)2.25 (2.07 to 2.44)3.06 (2.79 to 3.35)
Common serotypes - serotype 6B (n=368,341,357)11.14 (10.24 to 12.11)9.33 (8.55 to 10.19)9.92 (9.15 to 10.75)
Common serotypes - serotype 9V (n=368,342,357)1.91 (1.76 to 2.06)1.95 (1.80 to 2.10)1.99 (1.84 to 2.15)
Common serotypes - serotype 14 (n=366,344,358)6.61 (6.06 to 7.22)7.05 (6.42 to 7.74)6.91 (6.32 to 7.56)
Common serotypes - serotype 18C (n=362,341,354)1.95 (1.78 to 2.12)2.20 (2.01 to 2.41)2.48 (2.27 to 2.71)
Common serotypes - serotype 19F (n=362,342,353)4.51 (4.05 to 5.03)4.67 (4.23 to 5.14)6.51 (5.91 to 7.18)
Common serotypes - serotype 23F (n=362,340,353)3.35 (3.02 to 3.71)3.46 (3.14 to 3.82)3.10 (2.81 to 3.43)
Additional serotypes - serotype 1 (n=367,344,357)2.75 (2.53 to 2.99)2.95 (2.68 to 3.24)3.01 (2.75 to 3.30)
Additional serotypes - serotype 3 (n=366,343,356)0.75 (0.69 to 0.81)0.71 (0.65 to 0.77)0.80 (0.74 to 0.87)
Additional serotypes - serotype 5 (n=368,343,357)3.11 (2.87 to 3.37)2.63 (2.42 to 2.87)2.80 (2.60 to 3.02)
Additional serotypes - serotype 6A (n=366,342,355)7.52 (6.93 to 8.17)6.97 (6.41 to 7.59)6.83 (6.30 to 7.41)
Additional serotypes - serotype 7F (n=366,343,358)4.35 (4.01 to 4.72)4.24 (3.86 to 4.66)4.58 (4.21 to 4.98)
Additional serotype - serotype 19A (n=362,341,353)8.41 (7.73 to 9.14)8.32 (7.66 to 9.04)8.60 (7.91 to 9.36)
Statistical analysis
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Pilot Lot 2) · Difference in log-transformed gm: 0.02 · 95% CI -0.10 to 0.132-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Manufacturing Lot) · Difference in log-transformed gm: -0.29 · 95% CI -0.41 to -0.172-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 2) vs 13vPnC (Manufacturing Lot) · Difference in log-transformed gm: -0.31 · 95% CI -0.43 to -0.192-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Pilot Lot 2) · Difference in log-transformed gm: 0.18 · 95% CI 0.06 to 0.302-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Manufacturing Lot) · Difference in log-transformed gm: 0.12 · 95% CI -0.00 to 0.232-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 2) vs 13vPnC (Manufacturing Lot) · Difference in log-transformed gm: -0.06 · 95% CI -0.18 to 0.062-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Pilot Lot 2) · Difference in log-transformed gm: -0.02 · 95% CI -0.13 to 0.092-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Manufacturing Lot) · Difference in log-transformed gm: -0.04 · 95% CI -0.15 to 0.072-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 2) vs 13vPnC (Manufacturing Lot) · Difference in log-transformed gm: -0.02 · 95% CI -0.13 to 0.092-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Pilot Lot 2) · Difference in log-transformed gm: -0.06 · 95% CI -0.19 to 0.062-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Manufacturing Lot) · Difference in log-transformed gm: -0.04 · 95% CI -0.17 to 0.082-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 2) vs 13vPnC (Manufacturing Lot) · Difference in log-transformed gm: 0.02 · 95% CI -0.11 to 0.152-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Pilot Lot 2) · Difference in log-transformed gm: -0.12 · 95% CI -0.25 to 0.002-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Manufacturing Lot) · Difference in log-transformed gm: -0.24 · 95% CI -0.37 to -0.122-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 2) vs 13vPnC (Manufacturing Lot) · Difference in log-transformed gm: -0.12 · 95% CI -0.25 to 0.012-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Pilot Lot 2) · Difference in log-transformed gm: -0.03 · 95% CI -0.18 to 0.112-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Manufacturing Lot) · Difference in log-transformed gm: -0.37 · 95% CI -0.51 to -0.222-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 2) vs 13vPnC (Manufacturing Lot) · Difference in log-transformed gm: -0.33 · 95% CI -0.47 to -0.202-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Pilot Lot 2) · Difference in log-transformed gm: -0.03 · 95% CI -0.17 to 0.112-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Manufacturing Lot) · Difference in log-transformed gm: 0.08 · 95% CI -0.07 to 0.222-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 2) vs 13vPnC (Manufacturing Lot) · Difference in log-transformed gm: 0.11 · 95% CI -0.03 to 0.252-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Pilot Lot 2) · Difference in log-transformed gm: -0.07 · 95% CI -0.20 to 0.062-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Manufacturing Lot) · Difference in log-transformed gm: -0.09 · 95% CI -0.21 to 0.032-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 2) vs 13vPnC (Manufacturing Lot) · Difference in log-transformed gm: -0.02 · 95% CI -0.15 to 0.112-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Pilot Lot 2) · Difference in log-transformed gm: 0.06 · 95% CI -0.06 to 0.182-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Manufacturing Lot) · Difference in log-transformed gm: -0.07 · 95% CI -0.18 to 0.042-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 2) vs 13vPnC (Manufacturing Lot) · Difference in log-transformed gm: -0.13 · 95% CI -0.25 to -0.012-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Pilot Lot 2) · Difference in log-transformed gm: 0.17 · 95% CI 0.05 to 0.282-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Manufacturing Lot) · Difference in log-transformed gm: 0.10 · 95% CI -0.00 to 0.212-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 2) vs 13vPnC (Manufacturing Lot) · Difference in log-transformed gm: -0.06 · 95% CI -0.17 to 0.052-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Pilot Lot 2) · Difference in log-transformed gm: 0.08 · 95% CI -0.04 to 0.192-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Manufacturing Lot) · Difference in log-transformed gm: 0.10 · 95% CI -0.02 to 0.212-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 2) vs 13vPnC (Manufacturing Lot) · Difference in log-transformed gm: 0.02 · 95% CI -0.10 to 0.142-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Pilot Lot 2) · Difference in log-transformed gm: 0.03 · 95% CI -0.10 to 0.152-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Manufacturing Lot) · Difference in log-transformed gm: -0.05 · 95% CI -0.17 to 0.072-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 2) vs 13vPnC (Manufacturing Lot) · Difference in log-transformed gm: -0.08 · 95% CI -0.20 to 0.052-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Pilot Lot 2) · Difference in log-transformed gm: 0.01 · 95% CI -0.11 to 0.132-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 1) vs 13vPnC (Manufacturing Lot) · Difference in log-transformed gm: -0.02 · 95% CI -0.14 to 0.102-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
  • 13vPnC (Pilot Lot 2) vs 13vPnC (Manufacturing Lot) · Difference in log-transformed gm: -0.03 · 95% CI -0.15 to 0.082-sided 95% CI were constructed by back transformation of the CI for the mean of the logarithmically transformed assay results computed using the Student t distribution.
Other pre-specifiedPercentage of Participants Reporting Local Reactions in the Three 13vPnC Groups and 7vPnC Group: Infant Series Dose 1 (2 Months of Age)

Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.

Time frame:
Within 7 days after dose (2 months of age)
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Local Reactions in the Three 13vPnC Groups and 7vPnC Group: Infant Series Dose 1 (2 Months of Age)
percentage of participants13vPnC (Pilot Lot 1)13vPnC (Pilot Lot 2)13vPnC (Manufacturing Lot)7vPnC
Tenderness: Any (n=420, 409, 400, 212)62.464.162.567.0
Tenderness: Significant (n=348, 337, 345, 170)9.210.410.412.9
Induration: Any (n=356, 347, 352, 176)16.619.619.318.2
Induration: Mild (n=353, 344, 348, 173)14.716.915.516.2
Induration: Moderate (n=338, 328, 340, 167)3.65.85.03.6
Induration: Severe (n=333, 325, 335, 164)0.00.00.00.0
Erythema: Any (n=355, 352, 360, 180)19.425.023.122.8
Erythema: Mild (n=354, 352, 358, 180)18.124.721.221.7
Erythema: Moderate (n=334, 326, 337, 164)2.10.62.41.2
Erythema: Severe (n=333, 325, 335, 164)0.00.00.00.0
Other pre-specifiedPercentage of Participants Reporting Local Reactions in the Three 13vPnC Groups and 7vPnC Group: Infant Series Dose 2 (4 Months of Age)

Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 cm to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.

Time frame:
Within 7 days after dose (4 months of age)
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Local Reactions in the Three 13vPnC Groups and 7vPnC Group: Infant Series Dose 2 (4 Months of Age)
percentage of participants13vPnC (Pilot Lot 1)13vPnC (Pilot Lot 2)13vPnC (Manufacturing Lot)7vPnC
Tenderness: Any (n=354, 330, 337, 176)66.467.365.064.8
Tenderness: Significant (n=269, 231, 262, 132)9.77.412.211.4
Induration: Any (n=291, 248, 279, 141)24.422.628.717.7
Induration: Mild (n=288, 246, 276, 141)22.622.026.817.7
Induration: Moderate (n=270, 224, 255, 128)4.11.34.73.9
Induration: Severe (n=263, 221, 250, 127)0.00.00.40.0
Erythema: Any (n=292, 265, 281, 153)30.135.834.530.1
Erythema: Mild (n=289, 263, 279, 153)28.434.633.328.8
Erythema: Moderate (n=268, 223, 252, 128)3.41.83.23.1
Erythema: Severe (n=263, 221, 249, 127)0.00.00.00.0
Other pre-specifiedPercentage of Participants Reporting Local Reactions in the Three 13vPnC Groups and 7vPnC Group: Infant Series Dose 3 (6 Months of Age)

Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 cm to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.

Time frame:
Within 7 days after dose (6 months of age)
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Local Reactions in the Three 13vPnC Groups and 7vPnC Group: Infant Series Dose 3 (6 Months of Age)
percentage of participants13vPnC (Pilot Lot 1)13vPnC (Pilot Lot 2)13vPnC (Manufacturing Lot)7vPnC
Tenderness: Any (n=317, 304, 300, 156)62.560.955.064.7
Tenderness: Significant (n=248, 226, 237, 118)8.97.510.111.9
Induration: Any (n=263, 250, 262, 128)27.023.628.630.5
Induration: Mild (n=260, 249, 260, 127)24.622.527.329.1
Induration: Moderate (n=242, 221, 229, 114)4.14.13.97.0
Induration: Severe (n=237, 217, 227, 111)0.00.00.00.0
Erythema: Any (n=278, 262, 274, 137)39.635.937.639.4
Erythema: Mild (n=275, 260, 272, 135)37.133.836.438.5
Erythema: Moderate (n=243, 219, 231, 116)5.34.15.67.8
Erythema: Severe (n=237, 217, 227, 111)0.00.00.00.0
Other pre-specifiedPercentage of Participants Reporting Local Reactions in the Combined 13vPnC Group and 7vPnC Group: Toddler Dose (12 Months of Age)

Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 cm to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.

Time frame:
Within 7 days after dose (12 months of age)
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Local Reactions in the Combined 13vPnC Group and 7vPnC Group: Toddler Dose (12 Months of Age)
percentage of participantsCombined 13vPnC7vPnC
Tenderness: Any (n=826, 131)57.363.4
Tenderness: Significant (n=630, 97)6.74.1
Induration: Any (n=698, 110)31.543.6
Induration: Mild (n=689, 107)28.941.1
Induration: Moderate (n=627, 101)8.517.8
Induration: Severe (n=603, 93)0.00.0
Erythema: Any (n=749, 121)42.652.9
Erythema: Mild (n=735, 116)39.250.0
Erythema: Moderate (n=631, 104)10.621.2
Erythema: Severe (n=603, 93)0.00.0
Other pre-specifiedPercentage of Participants Reporting Systemic Events in the Three 13vPnC Groups and 7vPnC Group: Infant Series Dose 1 (2 Months of Age)

Systemic events (any fever ≥ 38 degrees Celsius \[C\], decreased appetite, irritability, increased sleep, decreased sleep, and hives \[urticaria\]) were reported using an electronic diary. Participants may be represented in more than 1 category.

Time frame:
Within 7 days after dose (2 months of age)
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Systemic Events in the Three 13vPnC Groups and 7vPnC Group: Infant Series Dose 1 (2 Months of Age)
percentage of participants13vPnC (Pilot Lot 1)13vPnC (Pilot Lot 2)13vPnC (Manufacturing Lot)7vPnC
Fever ≥38 but ≤39 degrees C (n=353, 337, 353, 173)24.623.424.626.0
Fever >39 but ≤40 degrees C (n=328, 319, 333, 161)0.60.30.91.2
Fever >40 degrees C (n=328, 319, 331, 160)0.00.00.30.6
Decreased appetite (n=393, 385, 386, 200)50.646.050.049.0
Irritability (n=435, 432, 433, 226)85.784.389.187.6
Increased sleep (n=425, 417, 402, 212)71.572.769.472.6
Decreased sleep (n=379, 377, 377, 194)44.146.942.246.4
Hives [urticaria] (n=333, 328, 335, 164)0.60.90.60.0
Other pre-specifiedPercentage of Participants Reporting Systemic Events in the Three 13vPnC Groups and 7vPnC Group: Infant Series Dose 2 (4 Months of Age)

Systemic events (any fever ≥ 38 degrees C, decreased appetite, irritability, increased sleep, decreased sleep, and hives \[urticaria\]) were reported using an electronic diary. Participants may be represented in more than 1 category.

Time frame:
Within 7 days after dose (4 months of age)
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Systemic Events in the Three 13vPnC Groups and 7vPnC Group: Infant Series Dose 2 (4 Months of Age)
percentage of participants13vPnC (Pilot Lot 1)13vPnC (Pilot Lot 2)13vPnC (Manufacturing Lot)7vPnC
Fever ≥38 but ≤39 degrees C (n=290, 250, 290, 143)33.436.435.528.0
Fever >39 but ≤40 degrees C (n=263, 216, 248, 124)3.43.23.60.0
Fever >40 degrees C (n=259, 214, 245, 124)0.40.00.00.0
Decreased appetite (n=322, 293, 325, 164)48.449.148.049.4
Irritability (n=377, 370, 376, 201)86.586.584.681.1
Increased sleep (n=332, 318, 343, 177)64.868.267.363.3
Decreased sleep (n=324, 291, 305, 159)49.148.844.648.4
Hives [urticaria] (n=263, 225, 253, 127)0.42.21.60.8
Other pre-specifiedPercentage of Participants Reporting Systemic Events in the Three 13vPnC Groups and 7vPnC Group: Infant Series Dose 3 (6 Months of Age)

Systemic events (any fever ≥ 38 degrees C, decreased appetite, irritability, increased sleep, decreased sleep, and hives \[urticaria\]) were reported using an electronic diary. Participants may be represented in more than 1 category.

Time frame:
Within 7 days after dose (6 months of age)
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Systemic Events in the Three 13vPnC Groups and 7vPnC Group: Infant Series Dose 3 (6 Months of Age)
percentage of participants13vPnC (Pilot Lot 1)13vPnC (Pilot Lot 2)13vPnC (Manufacturing Lot)7vPnC
Fever ≥38 but ≤39 degrees C (n=266, 246, 252, 132)26.327.631.732.6
Fever >39 but ≤40 degrees C (n=237, 219, 231, 113)2.53.75.66.2
Fever >40 degrees C (n=234, 216, 224, 111)0.00.50.00.9
Decreased appetite (n=286, 273, 286, 144)45.848.050.750.0
Irritability (n=352, 339, 347, 186)79.580.582.784.4
Increased sleep (n=289, 289, 286, 138)55.458.859.851.4
Decreased sleep (n=282, 272, 289, 147)42.650.448.456.5
Hives [urticaria] (n=239, 218, 229, 112)1.70.91.71.8
Other pre-specifiedPercentage of Participants Reporting Systemic Events in the Combined 13vPnC Group and 7vPnC Group: Toddler Dose (12 Months of Age)

Systemic events (any fever ≥ 38 degrees C, decreased appetite, irritability, increased sleep, decreased sleep, and hives \[urticaria\]) were reported using an electronic diary. Participants may be represented in more than 1 category.

Time frame:
Within 7 days after dose (12 months of age)
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Systemic Events in the Combined 13vPnC Group and 7vPnC Group: Toddler Dose (12 Months of Age)
percentage of participantsCombined 13vPnC7vPnC
Fever ≥38 but ≤39 degrees C (n=667, 107)28.829.9
Fever >39 but ≤40 degrees C (n=592, 95)4.45.3
Fever >40 degrees C (n=586, 93)1.00.0
Decreased appetite (n=790, 115)51.950.4
Irritability (n=943, 160)81.880.0
Increased sleep (n=779, 126)47.847.6
Decreased sleep (n=770, 117)46.942.7
Hives [urticaria] (n=607, 96)2.15.2

Adverse events

Collected over Baseline through 6 Month Follow-up after last study vaccination (18 Months). Local reactions and systemic events assessed within 7 days of dose: Infant Series Dose 1, 2, and 3 at 2, 4, and 6 months of age, respectively; Toddler Dose at 12 months of age.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Infant Series 13vPnC (Pilot Lot 1)—13/486 (2.7%)407/486 (83.7%)
Infant Series 13vPnC (Pilot Lot 2)—23/483 (4.8%)394/483 (81.6%)
Infant Series 13vPnC (Manufacturing Lot)—17/483 (3.5%)402/483 (83.2%)
Infant Series 7vPnC—15/244 (6.1%)207/244 (84.8%)
After the Infant Series Combined 13vPnC—25/1,445 (1.7%)88/1,445 (6.1%)
After the Infant Series 7vPnC—3/244 (1.2%)11/244 (4.5%)
Toddler Dose Combined 13vPnC—9/1,210 (0.7%)771/1,210 (63.7%)
Toddler Dose 7vPnC—1/208 (0.5%)128/208 (61.5%)
Post Toddler Dose 6-Month Follow-up Combined 13vPnC—21/1,443 (1.5%)37/1,443 (2.6%)
Post Toddler Dose 6-Month Follow-up 7vPnC—7/244 (2.9%)9/244 (3.7%)
Most frequent serious events
Showing 10 of 69
Most frequent serious events
EventInfant Series 13vPnC (Pilot Lot 1)Infant Series 13vPnC (Pilot Lot 2)Infant Series 13vPnC (Manufacturing Lot)Infant Series 7vPnCAfter the Infant Series Combined 13vPnCAfter the Infant Series 7vPnCToddler Dose Combined 13vPnCToddler Dose 7vPnCPost Toddler Dose 6-Month Follow-up Combined 13vPnCPost Toddler Dose 6-Month Follow-up 7vPnC
Respiratory syncytial virus bronchiolitisInfections and infestations2/4865/4834/4832/2441/14450/2440/12100/2081/14430/244
BronchiolitisInfections and infestations5/4862/4834/4832/2442/14450/2440/12101/2081/14430/244
PyrexiaGeneral disorders0/4863/4830/4832/2441/14450/2440/12100/2080/14430/244
PneumoniaInfections and infestations2/4861/4832/4832/2441/14451/2440/12101/2083/14431/244
Urinary tract infectionInfections and infestations1/4861/4831/4832/2440/14450/2441/12100/2080/14430/244
Otitis mediaInfections and infestations0/4863/4830/4830/2440/14450/2440/12100/2081/14432/244
DehydrationMetabolism and nutrition disorders0/4861/4833/4832/2441/14450/2441/12100/2080/14431/244
AsthmaRespiratory, thoracic and mediastinal disorders0/4860/4830/4830/2440/14450/2440/12100/2084/14432/244
Croup infectiousInfections and infestations0/4863/4830/4831/2440/14450/2440/12100/2081/14431/244
Respiratory distressRespiratory, thoracic and mediastinal disorders1/4863/4830/4831/2441/14450/2440/12100/2080/14430/244
Most frequent other events
Showing 10 of 450
Most frequent other events
EventInfant Series 13vPnC (Pilot Lot 1)Infant Series 13vPnC (Pilot Lot 2)Infant Series 13vPnC (Manufacturing Lot)Infant Series 7vPnCAfter the Infant Series Combined 13vPnCAfter the Infant Series 7vPnCToddler Dose Combined 13vPnCToddler Dose 7vPnCPost Toddler Dose 6-Month Follow-up Combined 13vPnCPost Toddler Dose 6-Month Follow-up 7vPnC
IrritabilityGeneral disorders373/435364/432386/433198/226——771/943128/160——
IrritabilityGeneral disorders326/377320/370318/376163/201——————
IrritabilityGeneral disorders280/352273/339287/347157/186——————
Increased sleepGeneral disorders304/425303/417279/402154/212——372/77960/126——
Increased sleepGeneral disorders215/332217/318231/343112/177——————
Tenderness (any)Skin and subcutaneous tissue disorders235/354222/330219/337114/176——————
Tenderness (any)Skin and subcutaneous tissue disorders262/420262/409250/400142/212——473/82683/131——
Tenderness (any)Skin and subcutaneous tissue disorders198/317185/304165/300101/156——————
Increased sleepGeneral disorders160/289170/289171/28671/138——————
Decreased sleepGeneral disorders120/282137/272140/28983/147——————

Baseline characteristics

Age Continuous
Age Continuous(months)13vPnC (Pilot Lot 1)13vPnC (Pilot Lot 2)13vPnC (Manufacturing Lot)7vPnCTotal
Mean2.2 ± 0.32.2 ± 0.32.2 ± 0.32.2 ± 0.32.2 ± 0.3
Sex/Gender, Customized
Sex/Gender, Customized(participants)13vPnC (Pilot Lot 1)13vPnC (Pilot Lot 2)13vPnC (Manufacturing Lot)7vPnCTotal
Female230226213115784
Male259260275131925
Unknown02103
08

Study locations

78 sites
  • Benton, Arkansas 72019, United States
  • Conway, Arkansas 72033, United States
  • Fayetteville, Arkansas 72703, United States
  • Jonesboro, Arkansas 72401, United States
  • Little Rock, Arkansas 72205, United States
  • North Little Rock, Arkansas 72117, United States
  • Downey, California 90242, United States
  • Fontana, California 92335, United States
  • Fountain Valley, California 92708, United States
  • Lakewood, California 90805, United States
  • Loma Linda, California 92354, United States
  • Moreno Valley, California 92557, United States
  • Paramount, California 90723, United States
  • Riverside, California 92505, United States
  • Rolling Hills Estates, California 90274, United States
  • Boulder, Colorado 80303, United States
  • Longmont, Colorado 80501, United States
  • Norwich, Connecticut 06360, United States
  • Palm Beach Gardens, Florida 33410, United States
  • Tampa, Florida 33606, United States
  • Atlanta, Georgia 30322, United States
  • Marietta, Georgia 30062, United States
  • Woodstock, Georgia 30189, United States
  • Nampa, Idaho 83686, United States
  • Chicago, Illinois 60647, United States
  • Dekalb, Illinois 60115, United States
  • Bardstown, Kentucky 40004, United States
  • Crestview Hills, Kentucky 41017, United States
  • Louisville, Kentucky 40202, United States
  • Louisville, Kentucky 40207, United States
  • Boston, Massachusetts 02111, United States
  • Boston, Massachusetts 02116, United States
  • Fall River, Massachusetts 02124, United States
  • Jamaica Plain, Massachusetts 02130, United States
  • Jackson, Mississippi 39216, United States
  • St. Louis, Missouri 63110, United States
  • Omaha, Nebraska 68127, United States
  • Omaha, Nebraska 68131, United States
  • Lebanon, New Hampshire 03756, United States
  • Whitehouse Station, New Jersey 08809, United States
  • Bronx, New York 10467, United States
  • Fishkill, New York 12524, United States
  • Hopewell Jct, New York 12533, United States
  • Ithaca, New York 14850, United States
  • Syracuse, New York 13202, United States
  • Cary, North Carolina 27518, United States
  • Durham, North Carolina 27704, United States
  • Durham, North Carolina 27705, United States
  • Sylva, North Carolina 28779, United States
  • Bismark, North Dakota 58501, United States
  • Fargo, North Dakota 58103, United States
  • Cincinnati, Ohio 45245, United States
  • Cleveland, Ohio 44121, United States
  • Huber Heights, Ohio 45424, United States
  • Kettering, Ohio 45429, United States
  • Mason, Ohio 45040, United States
  • Tulsa, Oklahoma 74127, United States
  • Kittanning, Pennsylvania 16201, United States
  • Latrobe, Pennsylvania 15650, United States
  • Pittsburgh, Pennsylvania 15227, United States
  • Pittsburgh, Pennsylvania 15236, United States
  • Pittsburgh, Pennsylvania 15241, United States
  • Clarksville, Tennessee 37043, United States
  • Franklin, Tennessee 37067, United States
  • Jackson, Tennessee 38305, United States
  • Kingsport, Tennessee 37660, United States
  • Galveston, Texas 77555, United States
  • San Antonio, Texas 78212, United States
  • Layton, Utah 84041, United States
  • Murray, Utah 84107, United States
  • South Jordan, Utah 84095, United States
  • Vienna, Virginia 22180, United States
  • Vancouver, Washington 98664, United States
  • Vancouver, Washington 98684, United States
  • Vancouver, Washington 98686, United States
  • LaCrosse, Wisconsin 54601, United States
  • Marshfield, Wisconsin 54449, United States
  • Monroe, Wisconsin 53566, United States
09

References and documents

Publications

  • Payton T, Girgenti D, Frenck RW, Patterson S, Love J, Razmpour A, Sidhu MS, Emini EA, Gruber WC, Scott DA. Immunogenicity, safety and tolerability of 3 lots of 13-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in the United States. Pediatr Infect Dis J. 2013 Aug;32(8):871-80. doi: 10.1097/INF.0b013e3182906499. PubMed 23584582 ↗
  • Bryant KA, Gurtman A, Girgenti D, Reisinger K, Johnson A, Pride MW, Patterson S, Devlin C, Gruber WC, Emini EA, Scott DA. Antibody responses to routine pediatric vaccines administered with 13-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2013 Apr;32(4):383-8. doi: 10.1097/INF.0b013e318279e9a9. PubMed 23104129 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2007, a primary completion of Jun 2009 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2010, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2007
First posted
Mar 7, 2007
Start
May 2007
Primary completionActual
Jun 2009
CompletionActual
Jun 2009
Results first posted
Jul 14, 2010
Last update
Oct 15, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00444457
Responsible party
Sponsor
First posted
Mar 7, 2007
Start date
May 2007
Primary completion
Jun 2009
Completion
Jun 2009
Results posted
Jul 14, 2010
Last update
Oct 15, 2012

Study contacts

Medical Monitor
study director · Wyeth is now a wholly owned subsidiary of Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 13-valent pneumococcal vaccine

Start the discussion